Hansa Biopharma price target lowered to SEK 111 from SEK 132 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Hansa Biopharma (HNSBF) to SEK 111 from SEK 132 and keeps a Buy rating on the shares after Imlifidase failed in the Phase 3 study.